HUMAN CALCITONIN IN THE TREATMENT OF PAGET'S BONE DISEASE

N. J.Y. Woodhouse; PH Bordier; M. Fisher; G. F. Joplin; M. Reiner; D. N. Kalu; G. V. Foster; I. Macintyre

doi:10.1016/S0140-6736(71)91657-6

HUMAN CALCITONIN IN THE TREATMENT OF PAGET'S BONE DISEASE

N. J.Y. Woodhouse, PH Bordier, M. Fisher, G. F. Joplin, M. Reiner, D. N. Kalu, G. V. Foster, I. Macintyre

Research output: Contribution to journal › Article › peer-review

98 Scopus citations

Abstract

Human synthetic calcitonin has produced a striking clinical and biochemical remission in each of five patients with Paget's disease treated for four to twelve months. Bone pain was relieved and skin temperature over affected limbs reduced. Elevated total urinary hydroxyproline levels fell to within the normal range and serum-alkaline-phosphatase to normal or near normal values. In two patients in whom quantitative histological studies were carried out, the number of osteoclasts was markedly reduced. The new bone formed during therapy had a normal lamellar structure. As assessed by the 47-calcium kinetic studies, the enhanced rate of bone-calcium turnover fell progressively. Calcium balance became positive or more positive. In each of the three patients studied, plasma-parathyroid-hormone levels were within the normal range after treatment for at least nine months. Two patients in remission relapsed slowly when calcitonin was withheld; they responded fully with further treatment.

Original language	English (US)
Pages (from-to)	1139-1143
Number of pages	5
Journal	The Lancet
Volume	297
Issue number	7710
DOIs	https://doi.org/10.1016/S0140-6736(71)91657-6
State	Published - Jun 5 1971
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(71)91657-6

Cite this

@article{c57e2c5d936240a6a1a28091d2fed361,

title = "HUMAN CALCITONIN IN THE TREATMENT OF PAGET'S BONE DISEASE",

abstract = "Human synthetic calcitonin has produced a striking clinical and biochemical remission in each of five patients with Paget's disease treated for four to twelve months. Bone pain was relieved and skin temperature over affected limbs reduced. Elevated total urinary hydroxyproline levels fell to within the normal range and serum-alkaline-phosphatase to normal or near normal values. In two patients in whom quantitative histological studies were carried out, the number of osteoclasts was markedly reduced. The new bone formed during therapy had a normal lamellar structure. As assessed by the 47-calcium kinetic studies, the enhanced rate of bone-calcium turnover fell progressively. Calcium balance became positive or more positive. In each of the three patients studied, plasma-parathyroid-hormone levels were within the normal range after treatment for at least nine months. Two patients in remission relapsed slowly when calcitonin was withheld; they responded fully with further treatment.",

author = "Woodhouse, {N. J.Y.} and PH Bordier and M. Fisher and Joplin, {G. F.} and M. Reiner and Kalu, {D. N.} and Foster, {G. V.} and I. Macintyre",

note = "Funding Information: human calcitonin; Dr. Len Deftos for the parathyroid-hormone immunoassays; and Mr. J. Martin for the preparation of the histological sections. This work was supported in part by the M.R.C. (N. J. Y. W.), the Swiss Academy of Sciences (M. R.), the American Heart Association (D. N. K. and G. V. F.), I.N.S.E.R.M. (Ph. B.), and the Wellcome Trust.",

year = "1971",

month = jun,

day = "5",

doi = "10.1016/S0140-6736(71)91657-6",

language = "English (US)",

volume = "297",

pages = "1139--1143",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "7710",

}

TY - JOUR

T1 - HUMAN CALCITONIN IN THE TREATMENT OF PAGET'S BONE DISEASE

AU - Woodhouse, N. J.Y.

AU - Bordier, PH

AU - Fisher, M.

AU - Joplin, G. F.

AU - Reiner, M.

AU - Kalu, D. N.

AU - Foster, G. V.

AU - Macintyre, I.

N1 - Funding Information: human calcitonin; Dr. Len Deftos for the parathyroid-hormone immunoassays; and Mr. J. Martin for the preparation of the histological sections. This work was supported in part by the M.R.C. (N. J. Y. W.), the Swiss Academy of Sciences (M. R.), the American Heart Association (D. N. K. and G. V. F.), I.N.S.E.R.M. (Ph. B.), and the Wellcome Trust.

PY - 1971/6/5

Y1 - 1971/6/5

N2 - Human synthetic calcitonin has produced a striking clinical and biochemical remission in each of five patients with Paget's disease treated for four to twelve months. Bone pain was relieved and skin temperature over affected limbs reduced. Elevated total urinary hydroxyproline levels fell to within the normal range and serum-alkaline-phosphatase to normal or near normal values. In two patients in whom quantitative histological studies were carried out, the number of osteoclasts was markedly reduced. The new bone formed during therapy had a normal lamellar structure. As assessed by the 47-calcium kinetic studies, the enhanced rate of bone-calcium turnover fell progressively. Calcium balance became positive or more positive. In each of the three patients studied, plasma-parathyroid-hormone levels were within the normal range after treatment for at least nine months. Two patients in remission relapsed slowly when calcitonin was withheld; they responded fully with further treatment.

AB - Human synthetic calcitonin has produced a striking clinical and biochemical remission in each of five patients with Paget's disease treated for four to twelve months. Bone pain was relieved and skin temperature over affected limbs reduced. Elevated total urinary hydroxyproline levels fell to within the normal range and serum-alkaline-phosphatase to normal or near normal values. In two patients in whom quantitative histological studies were carried out, the number of osteoclasts was markedly reduced. The new bone formed during therapy had a normal lamellar structure. As assessed by the 47-calcium kinetic studies, the enhanced rate of bone-calcium turnover fell progressively. Calcium balance became positive or more positive. In each of the three patients studied, plasma-parathyroid-hormone levels were within the normal range after treatment for at least nine months. Two patients in remission relapsed slowly when calcitonin was withheld; they responded fully with further treatment.

UR - http://www.scopus.com/inward/record.url?scp=0015211694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015211694&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(71)91657-6

DO - 10.1016/S0140-6736(71)91657-6

M3 - Article

C2 - 4102856

AN - SCOPUS:0015211694

SN - 0140-6736

VL - 297

SP - 1139

EP - 1143

JO - The Lancet

JF - The Lancet

IS - 7710

ER -

HUMAN CALCITONIN IN THE TREATMENT OF PAGET'S BONE DISEASE

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this